{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:11:55Z","timestamp":1788455515343,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The CoVID-TE model was developed with the aim of predicting venous thrombotic events (VTE) in cancer patients with Sars-Cov-2 infection. Moreover, it was capable of predicting hemorrhage and mortality 30\u00a0days following infection diagnosis. The model is pending validation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods\/patients<\/jats:title>\n                <jats:p>Multicenter retrospective study (10 centers). Adult patients with active oncologic disease\/ antineoplastic therapy with Sars-Cov-2 infection hospitalized between March 1, 2020 and March 1.  2022 were recruited. The primary endpoint was to study the association between the risk categories of the CoVID-TE model and the occurrence of thrombosis using the Chi-Square test. Secondary endpoints were to demonstrate the association between these categories and the occurrence of post-diagnostic Sars-Cov-2 bleeding\/ death events. The Kaplan\u2013Meier method was also used to compare mortality by stratification.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>263 patients were enrolled. 59.3% were men with a median age of 67\u00a0years. 73.8% had stage IV disease and lung cancer was the most prevalent tumor (24%). A total of 86.7% had an ECOG 0\u20132 and 77.9% were receiving active antineoplastic therapy. After a median follow-up of 6.83\u00a0months, the incidence of VTE, bleeding, and death 90\u00a0days after Sars-Cov-2 diagnosis in the low-risk group was 3.9% (95% CI 1.9\u20137.9), 4.5% (95% CI 2.3\u20138.6), and 52.5% (95% CI 45.2\u201359.7), respectively. For the high-risk group it was 6% (95% CI 2.6\u201313.2), 9.6% (95% CI 5.0\u201317.9), and 58.0% (95% CI 45.3\u201366.1). The Chi-square test for trends detected no statistically significant association between these variables (p\u2009&gt;\u20090.05). Median survival in the low-risk group was 10.15\u00a0months (95% CI 3.84\u201316.46), while in the high-risk group it was 3.68\u00a0months (95% CI 0.0\u20137.79). The differences detected were not statistically significant (p\u2009=\u20090.375).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The data from our series does not validate of the CoVID-TE as a model to predict thrombosis, hemorrhage, or mortality in cancer patients with Sars-Cov-2 infection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12094-023-03233-2","type":"journal-article","created":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T19:01:27Z","timestamp":1686423687000},"page":"171-177","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Validation of the CoVID-TE model as a tool to predict thrombosis, bleeding, and mortality in the oncology patient with Sars-Cov-2 infection: a study by the SEOM cancer and thrombosis group"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8687-4101","authenticated-orcid":false,"given":"Manuel","family":"S\u00e1nchez C\u00e1novas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Fern\u00e1ndez Garay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"G\u00f3mez Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Brozos V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Lobo de Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Garc\u00eda Adri\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vilma","family":"Pacheco-Barc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Cacho Lavin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mart\u00ednez de Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Manuela","family":"Mart\u00edn Fern\u00e1ndez de Soignie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Bel\u00e9n","family":"R\u00faperez Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Garc\u00eda Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Salvador Coloma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noel","family":"Blaya Boluda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Esperanza","family":"Guirao Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Gamb\u00edn Arroniz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J.","family":"Mu\u00f1oz Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,10]]},"reference":[{"issue":"7","key":"3233_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1055\/s-0040-1714275","volume":"46","author":"NA Horowitz","year":"2020","unstructured":"Horowitz NA, Brenner B. Thrombosis and hemostasis issues in cancer patients with COVID-19. Semin Thromb Hemost. 2020;46(7):785\u20138. https:\/\/doi.org\/10.1055\/s-0040-1714275.","journal-title":"Semin Thromb Hemost"},{"issue":"3","key":"3233_CR2","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.jvs.2020.05.015","volume":"72","author":"IH Khan","year":"2020","unstructured":"Khan IH, Savarimuthu S, Leung MST, Harky A. The need to manage the risk of thromboembolism in COVID-19 patients. J Vasc Surg. 2020;72(3):799\u2013804. https:\/\/doi.org\/10.1016\/j.jvs.2020.05.015.","journal-title":"J Vasc Surg"},{"issue":"5","key":"3233_CR3","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1158\/0008-5472.CAN-20-3691","volume":"81","author":"LM Lichtenberger","year":"2021","unstructured":"Lichtenberger LM, Vijayan KV. Is COVID-19-induced platelet activation a cause of concern for patients with cancer? Cancer Res. 2021;81(5):1209\u201311. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3691.","journal-title":"Cancer Res"},{"issue":"25","key":"3233_CR4","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1056\/NEJM200012213432504","volume":"343","author":"HT S\u00f8rensen","year":"2000","unstructured":"S\u00f8rensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med. 2000;343(25):1846\u201350. https:\/\/doi.org\/10.1056\/NEJM200012213432504. (PMID: 11117976).","journal-title":"N Engl J Med"},{"issue":"4","key":"3233_CR5","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","volume":"166","author":"HK Chew","year":"2006","unstructured":"Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(4):458\u201364. https:\/\/doi.org\/10.1001\/archinte.166.4.458. (PMID: 16505267).","journal-title":"Arch Intern Med"},{"issue":"7","key":"3233_CR6","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaoncol.2020.0980.PMID:32211820;PMCID:PMC7097836","volume":"6","author":"J Yu","year":"2020","unstructured":"Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan. China JAMA Oncol. 2020;6(7):1108\u201310. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0980.PMID:32211820;PMCID:PMC7097836.","journal-title":"China JAMA Oncol"},{"issue":"3","key":"3233_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","volume":"21","author":"W Liang","year":"2020","unstructured":"Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335\u20137. https:\/\/doi.org\/10.1016\/S1470-2045(20)30096-6. (PMID: 32066541).","journal-title":"Lancet Oncol"},{"key":"3233_CR8","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.eclinm.2020.100639","volume":"29","author":"MB Malas","year":"2020","unstructured":"Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020;29:100639. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100639. (PMID: 33251499).","journal-title":"EClinicalMedicine."},{"issue":"10","key":"3233_CR9","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1111\/jth.15463","volume":"19","author":"A Li","year":"2021","unstructured":"Li A, Kuderer NM, Hsu CY, Shyr Y, Warner JL, Shah DP, et al. The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19. J Thromb Haemost. 2021;19(10):2522\u201332. https:\/\/doi.org\/10.1111\/jth.15463. (PMID: 34260813).","journal-title":"J Thromb Haemost"},{"key":"3233_CR10","unstructured":"Dhand, N. K., & Khatkar, M. S. Statulator: An online statistical calculator. Sample Size Calculator for Estimating a Single Proportion. 2014. Accessed at http:\/\/statulator.com\/SampleSize\/ss1P.html"},{"issue":"7","key":"3233_CR11","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7.PMID:35772465;PMCID:PMC9236567","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, et al. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol. 2022;23(7):e334\u201347. https:\/\/doi.org\/10.1016\/S1470-2045(22)00160-7.PMID:35772465;PMCID:PMC9236567.","journal-title":"Lancet Oncol"},{"issue":"5","key":"3233_CR12","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1200\/JCO.19.01461","volume":"38","author":"NS Key","year":"2020","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: asco clinical practice guideline update. J Clin Oncol. 2020;38(5):496\u2013520. https:\/\/doi.org\/10.1200\/JCO.19.01461. (PMID: 31381464).","journal-title":"J Clin Oncol"},{"issue":"2","key":"3233_CR13","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s12094-019-02263-z","volume":"22","author":"AJ Mu\u00f1oz Mart\u00edn","year":"2020","unstructured":"Mu\u00f1oz Mart\u00edn AJ, Gallardo D\u00edaz E, Garc\u00eda Escobar I, Mac\u00edas Montero R, Mart\u00ednez-Mar\u00edn V, Pach\u00f3n Olmos V, et al. SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019). Clin Transl Oncol. 2020;22(2):171\u201386. https:\/\/doi.org\/10.1007\/s12094-019-02263-z. (PMID: 31981080).","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"3233_CR14","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1055\/s-0038-1675577.PMID:31249964;PMCID:PMC6524906","volume":"2","author":"V Pach\u00f3n","year":"2018","unstructured":"Pach\u00f3n V, Trujillo-Santos J, Dom\u00e8nech P, Gallardo E, Font C, Gonz\u00e1lez-Porras JR, et al. cancer-associated thrombosis: beyond clinical practice guidelines-a multidisciplinary (SEMI-SEOM-SETH) Expert consensus. TH Open. 2018;2(4):e373\u201386. https:\/\/doi.org\/10.1055\/s-0038-1675577.PMID:31249964;PMCID:PMC6524906.","journal-title":"TH Open"},{"issue":"22","key":"3233_CR15","doi-asserted-by":"publisher","first-page":"04786","DOI":"10.1016\/j.annonc.2022.12.014","volume":"34","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, Gerotziafas G, Langer F, Lecumberri R, et al. Venous thromboembolism in cancer patients: ESMO Clinical Practice Guideline. Ann Oncol. 2023;34(22):04786. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.014. (PMID: 36638869).","journal-title":"Ann Oncol"},{"issue":"1","key":"3233_CR16","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/07853890.2022.2034936.PMID:35118917;PMCID:PMC8820829","volume":"54","author":"W Wen","year":"2022","unstructured":"Wen W, Chen C, Tang J, Wang C, Zhou M, Cheng Y, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: a meta-analysis. Ann Med. 2022;54(1):516\u201323. https:\/\/doi.org\/10.1080\/07853890.2022.2034936.PMID:35118917;PMCID:PMC8820829.","journal-title":"Ann Med"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03233-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-023-03233-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-023-03233-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T14:30:23Z","timestamp":1704205823000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-023-03233-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,10]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["3233"],"URL":"https:\/\/doi.org\/10.1007\/s12094-023-03233-2","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,10]]},"assertion":[{"value":"1 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have not conflict of interests related to the development of this research project.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of\nthe institutional and\/or national research committee and with the 1964 Helsinki declaration and its later\namendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No informed consent is required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}